02359 WUXI APPTEC
- 34.300
- +0.050+0.15%
WUXI APPTEC News
Hong Kong stocks soar with the collective rise of CRO concept stocks, as the Federal Reserve is expected to cut interest rates and new industry orders are accelerating recovery.
CRO concept stocks rose collectively, as of the publication, Joinn Laboratories (06127) rose 2.96% to HKD 7.3; Wuxi AppTec (02359) rose 2.56% to HKD 34.05; Asymchem Laboratories (06821) rose 2.5% to HKD 40.95.
Hong Kong stocks are active | Early gains in CRO concept stocks, the Fed may start cutting interest rates in September, and overseas investment in innovative drugs has gradually shown an upward trend.
CRO concept stocks rose in early trading. As of the time of publication, Wuxi Bio (02269) rose by 4.68% to HK$10.74; Wuxi Apptec (02359) rose by 4.62% to HK$32.85; Tigermed (03347) rose by 3.17% to HK$29.3; Pharmaron (03759) rose by 2.48% to HK$8.28.
Express News | BlackRock's Long Position in H Shares of WuXi AppTec Decreases to 4.88% on Aug 20 From 5.53% - HKEX
WuXi AppTec (02359.HK) receives a shareholding increase of 0.5825 million shares by FMR LLC.
According to the latest equity disclosure data from the Hong Kong Stock Exchange, on August 16, 2024, wuxi apptec (02359.HK) acquired 0.5825 million shares at an average price of HKD 33.6006 per share, with a total investment of approximately HKD 19.5723 million. After the acquisition, the latest number of shares held by FMR LLC is 19.91642 million, and the shareholding ratio has increased from 4.99% to 5.15%.
Research Reports: Haitong Sec maintains a rating of 'Outperform' as WuXi AppTec's order growth rate increases rapidly.
Haitong Securities' research report pointed out that Wuxi AppTec (603259.SH) maintains a steady operating trend, with rapid growth in order backlog, and the full-year performance guidance remains unchanged. As of the end of June 2024, the company's order backlog was 43.1 billion yuan, a year-on-year increase of 33.2% excluding specific commercial production projects. The bank expects continued upward momentum in the CRO and CDMO industries, with the company fully leveraging the advantages of an integrated, end-to-end R&D service platform to empower customers in terms of capabilities and scale, and is expected to achieve comprehensive growth in all business lines. EPS for 2024-2026 is expected to be 3.29 and 3.
Hong Kong stock market anomaly | Asymchem Laboratories (06821) fell more than 4%, leading the CRO concept. The industry's performance is generally under pressure due to the decline in investment and financing in the pharmaceutical industry.
CRO concept stocks fell today. As of press time, Asymchem Laboratories (06821) fell 3.74%, at HKD 39.9; Tigermed (03347) fell 3.67%, at HKD 30.2; Pharmaron (03759) fell 3.06%, at HKD 8.55; Wuxi AppTec (02359) fell 2.88%, at HKD 32.05.
Monkeypox epidemic is fermenting! Biomedical stocks on the Hong Kong stock market continue to be active. Institutions are expected to see a concentrated bullish catalyst.
Which mid-term bullish trends are worth paying attention to in the continuously active Hong Kong biomedical sector? What are the highlights of the Wande Innovative Drugs Index outperforming the market since July?
Hong Kong stocks fluctuated | CXO concept stocks fell in early trading, Geopolitical game has yet to land, CXO industry prosperity still fluctuates.
CXO concept stocks fell in early trading. As of press time, Tigermed (03347) fell 5.89% to HKD 31.9; Pharmaron (03759) fell 4.04% to HKD 9.02; Wuxi AppTec (02359) fell 3.75% to HKD 33.35; and Frontage (01521) fell 1.35% to HKD 0.73.
Express News | JPMorgan Chase's Long Position in H-Shares of WuXi AppTec Decreases to 6.47% on Aug 5 From 7.15% - HKEX
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | Silo Pharma Shares Are Trading Higher After the Company Entered Into an Agreement With WuXi AppTec for a Preclinical Small Animal Study of SPU-16
Express News | Silo Pharma Inc - Enters Agreement With WuXi AppTec for Spu-16 Study
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Breaking News: Contract research organizations are all on the rise, with Genscript Bio Technology leading the way with a 7.56% increase and WuXi AppTec with a 5.57% increase.
On August 6th, CXO concept stocks rose across the board. As of press time, Genscript Bio (01548.HK) rose 7.56% to HKD 12.8; Wuxi Apptec (02359.HK) rose 5.57% to HKD 35.05; Pharmaron (03759.HK) rose 3.64% to HKD 9.96; Wuxi Bio (02269.HK) rose 3.06% to HKD 11.44. The market source is from Futubull. On the news front, on August 6th, Daly of the Federal Reserve stated that the economy has been slowing down for the past few months; regarding the upcoming meeting in September.
The concept of contract research organizations is on the rise. Wuxi AppTec (02359) rose by 4.97%. Institutions predict that the performance of the pharmaceutical sector will show a marginal improvement trend.
Jingu Finance News | The concept of contract research organizations is up across the board. As of press time, Genscript Bio (01548) rose 6.07%, Wuxi AppTec (02359) rose 4.97%, Viva Biotech (01873) rose 4%, and Pharmaron (03759) rose 3.64%. On the news front, Xingye Securities issued a research report stating that the market attention to the pharmaceutical sector has gradually recovered recently. Looking back, the pharmaceutical sector experienced a downtrend of more than 2 months, with the CSI 300 Index down 11.0% (as of the close of August 2), while the Shanghai and Shenzhen 300 Index was also down 6.1% during the same period. Currently, the pharmaceutical sector is valued
Wuxi AppTec (02359.HK) received a shareholding of 1.5193 million shares from JPMorgan.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on July 30, 2024, Wuxi Apptec (02359.HK) obtained an increase in shareholding from JPMorgan Chase & Co. with an average price of HKD 30.2002 per share, purchasing 1.5193 million shares, involving approximately HKD 45.8831 million. After the increase, JPMorgan Chase & Co.'s latest holding position is 28.5096 million shares, and the holding proportion has increased from 6.97% to 7.36%.
Hong Kong Shares Fall, Weighed by Risk-Off Sentiment -- Market Talk
Abnormal movement hits | CRO concept stocks lead the gains, the Fed's interest rate cuts will be bullish for CXO enterprise customers, and Shanghai issued a document supporting biomedical innovation.
On August 2nd, CRO concept stocks rose in early trading. As of press time, Tigermed (03347.HK) rose 5.67%, reporting 31.7 Hong Kong dollars; WuXi AppTec (02359.HK) rose 4.60%, reporting 33 Hong Kong dollars; Joinn Laboratories (06127.HK) rose 3.85%, reporting 7.56 Hong Kong dollars; Pharmaron (03759.HK) rose 3.80%, reporting 9.84 Hong Kong dollars. Market source: Futubull. On the news front, the Federal Reserve stated that if progress in combating inflation continues as desired, it may announce interest rate cuts at its September meeting. There are
Hong Kong Shares Fall 1.9%, Tracking Wall Street's Declines -- Market Talk
Analysis
Price Target
No Data
